灰指甲治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

2024年全球甲癬治療市場規模達42億美元，預計2034年將以5.3%的複合年成長率成長至69億美元。推動這一市場成長的因素包括：全球範圍內甲癬盛行率的不斷上升、人們對甲真菌感染風險認知的不斷提高，以及藥物療法的日益普及。與年齡相關的甲癬病例的增加進一步支持了這一市場的擴張。此外，線上藥局使用量的激增和消費者對自我治療的偏好也推動了市場的發展，因為透過電商平台取得非處方 (OTC) 抗真菌藥物變得更加容易。此外，糖尿病發生率的上升也促進了市場的成長，由於免疫系統功能減弱和血液循環不良，糖尿病會增加甲癬的風險。

人口老化正日益成為指甲真菌感染發生率上升的關鍵因素。隨著年齡的成長，人們的免疫系統往往會減弱，使他們更容易受到感染，包括甲癬。與年齡相關的因素，例如血液循環減少、指甲生長減緩以及皮膚屏障功能下降，都會增加真菌感染的風險。此外，老年人更容易患糖尿病或血液循環不良等疾病，這兩者都會進一步增加指甲真菌感染的可能性。隨著老齡化人口需要更多地關注其醫療保健需求，包括預防和管理這些感染，對有效治療的需求也在成長。

2024年，藥品市場價值達32億美元。口服抗真菌藥物被視為甲癬的一線治療藥物，其受歡迎程度正推動該市場的成長。伊曲康唑、特比萘芬、灰黃黴素和酮康唑等藥物應用廣泛，且在藥局易於獲取，促進了市場需求。人們對與甲癬相關的指甲健康和美容問題的日益重視也推動了對有效藥物的需求。

遠端甲下型甲癬 (DSO) 佔據了 2024 年最大的市場佔有率，達 68.3%。 DSO 是最常見的甲癬類型，會影響糖尿病患者和周邊循環功能減退等疾病患者，使他們更容易感染。隨著全球人口老化，預計 DSO 病例將會增加，這將進一步推動對局部和全身性抗真菌治療的需求。

2024年，美國甲癬治療市場規模達16億美元。該地區的高成長得益於人們對甲真菌感染認知的提高以及各種治療方案的普及。出於對美觀和衛生的追求，人們尋求早期發現和及時治療，以降低傳播率和相關併發症。美國廣泛的治療方案預計將在整個預測期內繼續支持該地區的市場擴張。

甲癬治療市場的一些主要參與者包括 Taro Pharmaceuticals、葛蘭素史克、強生服務、Azilda Family Foot Care、Merz Pharma、博士倫健康科學、諾華、高德美實驗室、雷迪博士實驗室、Moberg Pharma、Kaken Pharmaceuticals、Skin Logic Aesthetics、南夏洛特綜合血管外科和輝瑞。綜合血管外科和輝瑞。綜合血管外科和輝瑞。綜合血管外科和輝瑞。綜合血管外科和輝瑞。綜合血管外科和輝瑞。綜合血管外科和輝瑞。在甲癬治療市場，公司正在採取多種策略來鞏固其地位。這些措施包括擴大產品供應、專注於研發以推出新療法以及透過線上藥局增加其影響力。與電子商務平台和零售連鎖店合作以加強分銷也是關鍵策略，同時投資於消費者意識活動，教育患者了解甲癬的風險和治療方法。此外，公司正在最佳化生產流程，以確保提供負擔得起的高品質治療，這對於在競爭激烈的環境中搶佔市場佔有率至關重要。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 甲癬盛行率不斷上升
    • 治療方案的進步
    • 人們對甲癬潛在威脅的認知不斷提高
    • 越來越注重美觀
  • 產業陷阱與挑戰
    • 發展中地區缺乏意識
    • 甲癬治療藥物的副作用
• 成長潛力分析
• 監管格局
• 川普政府關稅
  • 對貿易的影響
    • 貿易量中斷
    • 報復措施
  • 對產業的影響
    • 供給側影響（原料）
      • 主要材料價格波動
      • 供應鏈重組
      • 生產成本影響
    • 需求面影響（售價）
      • 價格傳導至終端市場
      • 市佔率動態
      • 消費者反應模式
  • 受影響的主要公司
  • 策略產業反應
    • 供應鏈重組
    • 定價和產品策略
    • 政策參與
  • 展望與未來考慮
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按治療類型，2021 - 2034 年

• 主要趨勢
• 藥物
  • 口服抗黴菌藥物
  • 外用抗真菌藥物
• 雷射和光動力療法
• 手術

第6章：市場估計與預測：依疾病類型，2021 - 2034 年

• 主要趨勢
• 遠端甲下甲癬
• 近端甲下甲真菌病
• 白色表淺性甲真菌病
• 其他疾病類型

第7章：市場估計與預測：依性別，2021 - 2034 年

• 主要趨勢
• 男性
• 女性

第8章：市場估計與預測：依最終用途，2021 - 2034 年

• 主要趨勢
• 醫院
• 皮膚科診所
• 居家照護環境
• 門診手術中心

第9章：市場估計與預測：按地區，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第10章：公司簡介

• Azilda Family Foot Care
• Bausch Health Sciences
• Dr. Reddy's Laboratories
• Galderma Laboratories
• GlaxoSmithKline
• Johnson & Johnson Services
• Kaken Pharmaceuticals
• Merz Pharma
• Moberg Pharma
• Novartis
• Pfizer
• Skin Logic Aesthetics
• South Charlotte General and Vascular Surgery
• Taro Pharmaceuticals

The Global Onychomycosis Treatment Market was valued at USD 4.2 billion in 2024 and is estimated to grow at a CAGR of 5.3% to reach USD 6.9 billion by 2034.This market growth is driven by the increasing prevalence of onychomycosis worldwide, heightened awareness about the risks associated with nail fungal infections, and the growing adoption of drug therapies for treatment. The rise in age-related cases of onychomycosis further supports this market expansion. Additionally, the surge in online pharmacy usage and consumer preference for self-treatment has propelled the market, as it has become easier to access over the counter (OTC) antifungal medications via e-commerce platforms. Furthermore, the rising incidence of diabetes, which heightens the risk of onychomycosis due to weakened immune systems and poor circulation, is also contributing to the market's growth.

The aging population is increasingly becoming a key factor in the rising incidence of nail fungal infections. As individuals age, their immune systems often weaken, making them more susceptible to infections, including onychomycosis. Age-related factors such as reduced blood circulation, slower nail growth, and a decline in skin barrier function contribute to the higher risk of developing fungal infections. Moreover, older adults are more likely to suffer from conditions like diabetes or poor circulation, both of which further elevate the likelihood of fungal nail infections. The demand for effective treatments is growing as the aging population requires more attention to their healthcare needs, including the prevention and management of these infections.

The drug segment was valued at USD 3.2 billion in 2024. The popularity of oral antifungal agents, which are considered the first-line treatment for onychomycosis, is fueling this segment's growth. Medications like itraconazole, terbinafine, griseofulvin, and ketoconazole are widely used, with easy availability in pharmacies enhancing market demand. The growing emphasis on nail health and cosmetic concerns related to onychomycosis also boosts the need for effective drugs.

The distal subungual onychomycosis (DSO) segment accounted for the largest market share of 68.3% in 2024. As the most common form of onychomycosis, DSO affects individuals with conditions such as diabetes and those with reduced peripheral circulation, which makes them more prone to infections. As the global population ages, DSO cases are expected to increase, further driving the need for both topical and systemic antifungal treatments.

U.S. Onychomycosis Treatment Market was valued at USD 1.6 billion in 2024. High regional growth is attributed to increased awareness of nail fungal infections and the availability of various treatment options. The demand for aesthetic appeal and hygiene drives people to seek early detection and timely treatment, reducing transmission rates and associated complications. The wide range of treatment options available in the U.S. is expected to continue supporting market expansion in the region throughout the forecast period.

Some of the key players in the Onychomycosis Treatment Market include Taro Pharmaceuticals, GlaxoSmithKline, Johnson & Johnson Services, Azilda Family Foot Care, Merz Pharma, Bausch Health Sciences, Novartis, Galderma Laboratories, Dr. Reddy's Laboratories, Moberg Pharma, Kaken Pharmaceuticals, Skin Logic Aesthetics, South Charlotte General and Vascular Surgery, and Pfizer. In the Onychomycosis Treatment Market, companies are adopting several strategies to strengthen their position. These include expanding product offerings, focusing on research and development to introduce novel treatments, and increasing their presence through online pharmacies. Partnerships with e-commerce platforms and retail chains to enhance distribution are also key strategies, along with investments in consumer awareness campaigns to educate patients on the risks and treatments for onychomycosis. Moreover, companies are optimizing manufacturing processes to ensure the availability of affordable and high-quality treatments, which is crucial for capturing market share in the competitive landscape.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of onychomycosis
    • 3.2.1.2 Advancement in treatment options
    • 3.2.1.3 Growing awareness about the potential threats of onychomycosis
    • 3.2.1.4 Increasing focus on aesthetic appearance
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of awareness in developing regions
    • 3.2.2.2 Side effects associated with onychomycosis treatment drugs
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Trump administration tariffs
  • 3.5.1 Impact on trade
    • 3.5.1.1 Trade volume disruptions
    • 3.5.1.2 Retaliatory measures
  • 3.5.2 Impact on the Industry
    • 3.5.2.1 Supply-side impact (raw materials)
      • 3.5.2.1.1 Price volatility in key materials
      • 3.5.2.1.2 Supply chain restructuring
      • 3.5.2.1.3 Production cost implications
    • 3.5.2.2 Demand-side impact (selling price)
      • 3.5.2.2.1 Price transmission to end markets
      • 3.5.2.2.2 Market share dynamics
      • 3.5.2.2.3 Consumer response patterns
  • 3.5.3 Key companies impacted
  • 3.5.4 Strategic industry responses
    • 3.5.4.1 Supply chain reconfiguration
    • 3.5.4.2 Pricing and product strategies
    • 3.5.4.3 Policy engagement
  • 3.5.5 Outlook and future considerations
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Drugs
  • 5.2.1 Oral antifungal drugs
  • 5.2.2 Topical antifungal drugs
• 5.3 Laser and photodynamic therapy
• 5.4 Surgery

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Distal subungual onychomycosis
• 6.3 Proximal subungual onychomycosis
• 6.4 White superficial onychomycosis
• 6.5 Other disease types

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Male
• 7.3 Female

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Dermatology clinics
• 8.4 Homecare settings
• 8.5 Ambulatory surgical centers

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Azilda Family Foot Care
• 10.2 Bausch Health Sciences
• 10.3 Dr. Reddy's Laboratories
• 10.4 Galderma Laboratories
• 10.5 GlaxoSmithKline
• 10.6 Johnson & Johnson Services
• 10.7 Kaken Pharmaceuticals
• 10.8 Merz Pharma
• 10.9 Moberg Pharma
• 10.10 Novartis
• 10.11 Pfizer
• 10.12 Skin Logic Aesthetics
• 10.13 South Charlotte General and Vascular Surgery
• 10.14 Taro Pharmaceuticals